Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.82 |
| ▸ | ACHE | P22303 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthine SCHEMBL4295220 | 0.98 | GDA (0.79) | GDAACHEALDH1A1PNPGRIA1 | |
| Uric Acid SCHEMBL3669633 | 0.92 | GDA (0.70) | GDAACHEALDH1A1PNPGRIA1 | |
| Xanthine SCHEMBL4965 | 0.91 | GDA (1.00) | GDAACHEALDH1A1PNPXDH | |
| Xanthine SCHEMBL2352524 | 0.91 | GDA (1.00) | GDAACHEALDH1A1PNPXDH | |
| Xanthine SCHEMBL29669592 | 0.91 | GDA (1.00) | GDAACHEALDH1A1PNPXDH | |
| Xanthine SCHEMBL2454001 | 0.89 | GDA (0.96) | GDAACHEALDH1A1PNPXDH | |
| Xanthine SCHEMBL1507586 | 0.89 | GDA (0.96) | GDAACHEALDH1A1PNPGRIA1 | |
| Xanthine SCHEMBL7044227 | 0.89 | GDA (0.96) | GDAACHEALDH1A1PNPXDH | |
| Xanthine SCHEMBL7044230 | 0.89 | GDA (0.96) | GDAACHEALDH1A1PNPXDH | |
| Xanthine SCHEMBL6783299 | 0.89 | GDA (0.96) | GDAACHEALDH1A1PNPXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2720 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164625-A2 | MODIFIED PLANT VIRUS SYSTEM FOR DELIVERY OF NUCLEIC ACIDS INTO MAMMALIAN CELLS | GEORGIA TECH RESEARCH CORPORATION (US) | 2023-08-31 | — | — | WO | claimed |
| US-12042531-B2 | Breast and ovarian cancer vaccines | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024151709-A1 | COMPOSITIONS FOR INDUCING OR RESCUING GLYCOLYSIS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2017015637-A9 | HIGH-THROUGHPUT SCREENING OF REGULATORY ELEMENT FUNCTION WITH EPIGENOME EDITING TECHNOLOGIES | DUKE UNIVERSITY (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240226260-A9 | VACCINE COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF URINARY TRACT INFECTIONS | DUKE UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| US-20240226291-A9 | COMBINATION OF NOVEL VACCINES AGAINST ZIKA VIRUS AND DNA ANTIBODY CONSTRUCTS FOR USE AGAINST ZIKA VIRUS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2024-07-11 | — | — | US | disclosed |
| US-20240226265-A9 | LASSA VIRUS VACCINE AND USES THEREOF | INOVIO PHARMACEUTICALS INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240229152-A9 | Methods of Treatment of High-Grade Squamous Intraepithelial Lesion (HSIL) | INOVIO PHARMACEUTICALS INC (US) | 2024-07-11 | — | — | US | disclosed |
| EP-4396328-A2 | HETEROHEXAMERIC FUSION CONSTRUCTS FOR PROTEIN EXPRESSION IN CYANOBACTERIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-4396209-A1 | METHODS OF PRODUCING HUMAN MILK OLIGOSACCHARIDES AND COMPOSITIONS THEREOF | Amyris, Inc. (US) | 2024-07-10 | — | — | EP | disclosed |
| US-5273885-A | Using a polyiodothyronine analog of a phenyl compound containing a hydroxyl group ortho to an iodine | SYNTEX (U.S.A.) INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5185257-A | Thermostable xanthine oxidase from Arthrobacter luteus | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1993-02-09 | — | — | US | disclosed |
| CN-1041880-A | Antibiotic 6270 and its salt used as anti-coccidiosis agent and feed additive | KAKEN PHARMACENTICAL CO LTD (JP) | 1990-05-09 | — | — | CN | disclosed |
| US-4376825-A | ENZYME-BOUND LIGANDS WITH FREE REACTIVE SITES WHICH CAN BIND RECEPTORS | SYVA COMPANY (US) | 1983-03-15 | — | — | US | disclosed |
| US-4282325-A | FOR AMPLIFICATION IN ASSAYS | SYVA COMPANY (US) | 1981-08-04 | — | — | US | disclosed |
| US-4203802-A | ENZYME BOUND TO AN ESTROGEN LIGAND | SYVA COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
| US-4190496-A | RECEPTOR, LIGAND, AND ENZYME-BOUND | SYVA COMPANY (US) | 1980-02-26 | — | — | US | disclosed |
| US-4067774-A | Compounds for enzyme amplification assay | SYVA COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-3975237-A | LIGANDS | SYVA COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3966556-A | Compounds for enzyme amplification assay methadone analogs | SYVA COMPANY (US) | 1976-06-29 | — | — | US | disclosed |